News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
92,911 Results
Type
Article (10785)
Company Profile (21)
Press Release (81640)
Multimedia
Podcasts (88)
Webinars (12)
Section
Business (35037)
Career Advice (551)
Deals (6054)
Drug Delivery (102)
Drug Development (12818)
Employer Resources (44)
FDA (2031)
Job Trends (2173)
News (51028)
Policy (4983)
Tag
2027 BioCapital Standard (1)
2027 Genetown Standard (2)
2027 Pharm Country Standard (3)
Academia (171)
Accelerated approval (11)
ADA (13)
Adcomms (21)
Allergies (40)
Alliances (8253)
ALS (50)
Alzheimer's disease (343)
Antibody-drug conjugate (ADC) (133)
Approvals (1973)
Artificial intelligence (205)
ASCO (58)
Autoimmune disease (71)
Automation (9)
Bankruptcy (55)
Best Places to Work (1203)
BIO (21)
Biologics (1)
BIOSECURE Act (9)
Biosimilars (89)
BioSpace Insights (60)
Biotechnology (13)
Bladder cancer (40)
Brain cancer (11)
Breast cancer (75)
Cancer (1025)
Cardiovascular disease (160)
Career advice (461)
Career pathing (28)
CAR-T (58)
CDC (13)
CDMO (70)
Celiac Disease (1)
Cell therapy (149)
Cervical cancer (5)
Clinical research (11128)
Collaboration (548)
Commercialization (3)
Company closure (3)
Compensation (124)
Complete response letters (38)
COVID-19 (460)
CRISPR (9)
C-suite (338)
Cystic fibrosis (14)
Data (1045)
Decentralized trials (1)
Denatured (13)
Depression (41)
Dermatology (36)
Diabetes (121)
Diagnostics (553)
Digital health (13)
Diversity (8)
Diversity, equity & inclusion (11)
Drug discovery (129)
Drug pricing (166)
Drug shortages (25)
Duchenne muscular dystrophy (87)
Earnings (10192)
Editorial (47)
Employer branding (6)
Employer resources (50)
Events (12637)
Executive appointments (280)
FDA (2552)
Friedreich's ataxia (2)
Frontotemporal dementia (5)
Funding (355)
Gene editing (30)
Generative AI (37)
Gene therapy (135)
GLP-1 (492)
Government (852)
Grass and pollen (1)
Guidances (47)
Healthcare (1559)
Hematology (24)
HIV (18)
Huntington's disease (20)
Idiopathic pulmonary fibrosis (2)
IgA nephropathy (21)
Immunology and inflammation (161)
Immuno-oncology (38)
Indications (20)
Infectious disease (553)
Inflammatory bowel disease (40)
Inflation Reduction Act (6)
Influenza (30)
Intellectual property (46)
Interviews (76)
IPO (2124)
IRA (42)
Job creations (850)
Job search strategy (389)
JPM (39)
Kidney cancer (3)
Labor market (81)
Layoffs (239)
Leadership (31)
Legal (1139)
Licensing (8)
Liver cancer (19)
Longevity (5)
Lung cancer (147)
Lymphoma (94)
Machine learning (16)
Management (24)
Manufacturing (388)
Marketing (3)
MASH (57)
Medical device (420)
Medtech (427)
Mergers & acquisitions (4087)
Metabolic disorders (577)
mRNA (59)
Multiple sclerosis (40)
NASH (9)
Netherlands (1)
Neurodegenerative disease (108)
Neuropsychiatric disorders (49)
Neuroscience (743)
Neurotech (1)
NextGen: Class of 2026 (642)
Non-profit (155)
Now hiring (52)
Obesity (404)
Opinion (169)
Ovarian cancer (24)
Pain (74)
Pancreatic cancer (61)
Parkinson's disease (71)
Partnered (11)
Patents (131)
Patient recruitment (96)
Peanut (5)
People (10664)
Pharmaceutical (12)
Pharmacy benefit managers (22)
Phase 1 (3070)
Phase 2 (5040)
Phase 3 (4315)
Pipeline (1705)
Policy (195)
Postmarket research (290)
Preclinical (1052)
Press Release (4)
Prostate cancer (59)
Psychedelics (30)
Radiopharmaceuticals (90)
Rare diseases (286)
Real estate (979)
Recruiting (22)
Regulatory (4111)
Reports (16)
Research institute (221)
Resumes & cover letters (99)
Rett syndrome (1)
RNA editing (10)
RSV (30)
Schizophrenia (72)
Series A (66)
Series B (43)
Service/supplier (2)
Sickle cell disease (18)
Special edition (21)
Spinal muscular atrophy (44)
Sponsored (9)
Startups (750)
Stomach cancer (10)
Supply chain (53)
Tariffs (93)
The Weekly (73)
Vaccines (215)
Venture capital (87)
Weight loss (336)
Women's health (32)
Worklife (9)
Date
Today (7)
Last 7 days (94)
Last 30 days (357)
Last 365 days (4710)
2026 (3257)
2025 (4739)
2024 (5228)
2023 (5734)
2022 (8118)
2021 (7665)
2020 (6678)
2019 (5440)
2018 (4357)
2017 (6187)
2016 (5394)
2015 (5403)
2014 (3331)
2013 (2867)
2012 (2888)
2011 (2852)
2010 (2425)
Location
Africa (186)
Alabama (6)
Arizona (17)
Arkansas (1)
Asia (9571)
Australia (821)
California (1398)
Canada (621)
China (366)
Colorado (88)
Connecticut (111)
Delaware (50)
Europe (20980)
Florida (388)
Georgia (13)
Hawaii (1)
Idaho (3)
Illinois (121)
India (58)
Indiana (60)
Iowa (2)
Japan (226)
Kansas (47)
Kentucky (2)
Louisiana (3)
Maryland (235)
Massachusetts (1173)
Michigan (27)
Minnesota (24)
Mississippi (2)
Missouri (4)
Montana (1)
Nebraska (3)
Nevada (9)
New Hampshire (3)
New Jersey (810)
New Mexico (16)
New York (396)
North Carolina (199)
Northern California (571)
Ohio (73)
Oklahoma (1)
Oregon (7)
Pennsylvania (419)
Puerto Rico (17)
Rhode Island (8)
South America (237)
South Carolina (3)
Southern California (686)
Tennessee (18)
Texas (134)
United States (5794)
Utah (22)
Virginia (25)
Washington D.C. (19)
Washington State (194)
West Virginia (1)
Wisconsin (15)
Wyoming (1)
92,911 Results for "lantern pharma".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update
August 14, 2026
·
19 min read
Press Releases
Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET
August 7, 2026
·
4 min read
Press Releases
Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer
July 28, 2026
·
12 min read
Press Releases
Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers
July 23, 2026
·
7 min read
Press Releases
Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates
May 17, 2026
·
19 min read
Press Releases
Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine
August 3, 2026
·
10 min read
Press Releases
Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026
May 12, 2026
·
4 min read
Press Releases
Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor
May 13, 2026
·
8 min read
Press Releases
Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
March 31, 2026
·
19 min read
Press Releases
Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer
June 2, 2026
·
11 min read
1 of 9,292
Next
